Clinical Trial Update: Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study) [Phase 2]

View source ↗

Summary

A completed Phase 2 prospective study (PrONTO) evaluating OCT-guided ranibizumab (Lucentis) treatment for neovascular age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: University of Miami | Conditions: Neovascular Age-Related Macular Degeneration | Phase 2 | Status: COMPLETED